Loading stock data…
MIRA Pharmaceuticals (MIRA)
$0.88-0.05 (-4.97%)
Market ClosedLast close Jul 24
MIRA Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MIRA Pharmaceuticals, Inc. in the Healthcare sector is trading at $0.88 with a market capitalization of $40M. The stock is currently near its 52-week low of $0.83, remaining 27.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.10M↑ | -$5.82M↓ | -$1.32M↑ | -$1.55M↑ | -$1.81M |
| Net Income | -$1.15M↑ | -$5.98M↓ | -$1.14M↑ | -$1.54M↑ | -$1.78M |
Peer Comparison
JNJUNHPFE
Fundamentals
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican righ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$39.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-104.92%
Volume
Today's trading volume
87,034
Recent News
Tapestry patents AI data analytics tech
The Coach owner said it is trimming the time it takes to analyze data through its newly patented AI technology.
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora Cannabis Announced Refocused Strategy as Global Medical Sales Hit Record High in 2026 Third Quarter Canopy Growth Reported Mixed Results in its Fiscal Third Quarter of 2026 Cronos Group Launched Premium Lord Jones Brand in Israel in Global Expansion Push Key Takeaways; Psychedelic Sector Clearmind Announced the Inclusion of its […]
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks fell late Thursday afternoon with the NYSE Health Care Index down 0.2% and the He